Precision NanoSystems Technology Included in Newly Opened Non-Coding RNA Precision Diagnostics and Therapeutics Core Facility

VANCOUVER, Jan. 24, 2018 /PRNewswire/ - Precision NanoSystems (PNI) is honored to provide the NanoAssemblr technology as part of a collaboration with The Cancer Center at Beth Israel Deaconess Medical Center and their recently opened Non-Coding RNA Precision Diagnostics and Therapeutics Core Facility. This new state-of-the-art facility is dedicated to the study of non-coding RNAs (ncRNA), which play an important role in regulating gene expression and are important for understanding, detecting, and treating disease. NanoAssemblr technology plays a complementary role by overcoming challenges in making gene-delivery nanoparticles for research and drug development.

“An important consideration for providing the NanoAssemblr Platform is the critical role the ncRNA Core Facility is poised to play in the revolution of Personalized Medicine. Nanomedicines are clinically validated for delivering nucleic acids to the site of disease, which overcomes a crucial technological challenge in ncRNA research and genetic medicine development,” said Euan Ramsay, COO and co-founder, PNI. “Additionally, the Facility’s accessibility to other major academic institutions and the pharma community in the Boston/Cambridge area furthers our goal to lead the charge in providing an accessible solution for the discovery and development of molecularly tailored & targeted medicines and aligns with PNI’s philosophy of advancing Personalized Medicine.”

The new technology should speed up the discovery, development and manufacturing of nanomedicine and facilitate a roadmap to improved treatments for patients by accelerating the development of personalized therapies.

“We are excited about this promising collaboration and hope that it will propel our work forward as the ncRNA Core Facility focuses on the non-coding RNA portions of the genome for discovery of novel biomarkers and targets for therapeutics from human disease tissue and clinical trial specimens,” said Frank Slack, Director of the Harvard Medical School Initiative for RNA Medicine (HIRM) at BIDMC.

The NanoAssemblr platform located at the ncRNA Core Facility is three instruments that collectively support each stage of the drug discovery and development process. The NanoAssemblr Spark™ produces microlitre volumes of nanomedicines for discovery research; the NanoAssemblr Benchtop manufactures 1 - 15 mL of nanomedicine formulations per run for pre-clinical nanomedicine development and optimization; the NanoAssemblr Blaze™ can manufacture up to 1 L of nanomedicines, which allows pre-clinical testing of the nanomedicines in a disease model. For more information on Precision NanoSystems, visit www.precisionnanosystems.com

About Precision NanoSystems, Inc.
Precision NanoSystems Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI’s proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com.

SOURCE Precision Nanosystems